For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi.

Weight-loss medication like Semaglutide and Tirzepatide has seen a rise in demand, causing a boom in sales. This exploding ...

Losing weight by dieting (restricting energy) includes, along with fat loss, losing lean mass, about half of which is ...

In 2024, a plethora of novel therapeutic strategies for kidney disease progressed to clinical trials, including an RNA interference therapeutic, a glucagon-like peptide 1 receptor agonist ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...